| Code | CSB-RA025833MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Bevacizumab-nwgd, targeting vascular endothelial growth factor A (VEGFA). VEGFA is a critical signaling protein that promotes angiogenesis by stimulating the proliferation and migration of endothelial cells and increasing vascular permeability. This growth factor plays essential roles in both physiological processes such as wound healing and pathological conditions including tumor vascularization, diabetic retinopathy, and age-related macular degeneration. VEGFA overexpression is strongly associated with cancer progression, as tumors exploit angiogenesis to sustain growth and facilitate metastasis.
Bevacizumab-nwgd is an FDA-approved biosimilar therapeutic antibody that functions by binding to VEGFA and preventing its interaction with VEGF receptors on endothelial cells, thereby inhibiting angiogenesis. This research-grade biosimilar provides investigators with a valuable tool for studying VEGFA-mediated signaling pathways, angiogenesis mechanisms, and anti-angiogenic strategies in various disease models. The antibody supports investigations in oncology, ophthalmology, and vascular biology research contexts.
There are currently no reviews for this product.